Puppo F, Pellicci R, Brenci S, Nocera A, Morelli N, Dardano G, Bertocchi M, Antonucci A, Ghio M, Scudeletti M
Department of Internal Medicine, University of Genoa, Italy.
Hum Immunol. 1994 Jul;40(3):166-70. doi: 10.1016/0198-8859(94)90063-9.
The serum levels of sHLA-I have been determined in 16 patients following liver transplantation. sHLA-I levels did not show remarkable variations in six patients without evidence of transplant-related complications. sHLA-I levels strongly increased in 10 patients undergoing acute rejection episodes. In these patients, an average 20% daily increase of sHLA-I levels was detected on the 6 days preceding and on the 2 days following the rejection episode. A fast decrease of sHLA-I levels was observed in seven patients following treatment of acute rejection with anti-CD3 mAb. The serum level of sHLA-I antigens positively correlated with ALT serum level and inversely correlated with PT. The determination of sHLA-I in serum may therefore be proposed as a useful marker in the monitoring of patients following liver transplantation. The increase of sHLA-I antigens may predict the onset of acute rejection whereas their decrease may be related to a good response of acute rejection to immunosuppressive treatment.
已对16例肝移植患者的血清可溶性人类白细胞抗原I类分子（sHLA-I）水平进行了测定。在6例无移植相关并发症迹象的患者中，sHLA-I水平未显示出明显变化。10例发生急性排斥反应的患者中，sHLA-I水平显著升高。在这些患者中，在排斥反应发作前6天和发作后2天检测到sHLA-I水平平均每天增加20%。7例接受抗CD3单克隆抗体治疗急性排斥反应的患者中观察到sHLA-I水平迅速下降。sHLA-I抗原的血清水平与谷丙转氨酶（ALT）血清水平呈正相关，与凝血酶原时间（PT）呈负相关。因此，血清中sHLA-I的测定可作为肝移植患者监测中的一个有用标志物。sHLA-I抗原的增加可能预示急性排斥反应的发生，而其降低可能与急性排斥反应对免疫抑制治疗的良好反应有关。
